Receiving, storing, and working with SR-17018 safely.

As of the review date, SR-17018 does not appear to be scheduled under the U.S. Controlled Substances Act. Classification outside the U.S. is jurisdiction-specific and should be verified before import, possession, or use.

This classification is not permanent. Novel opioids and their research analogues are reviewed periodically by the US Drug Enforcement Administration and by comparable authorities in other jurisdictions. Laboratory managers preparing to import or possess SR-17018 in quantity should confirm current classification with their institution's regulatory affairs office before the material arrives, not after.

Regardless of the federal scheduling position, many institutions treat synthetic μ-opioid receptor agonists as controlled in practice and require DEA-registered storage, restricted-access logging, and inventory reconciliation equivalent to Schedule II material. SR17 Labs follows those expectations at our end; our recommendation is that you do the same at yours.

SR-17018 is appropriate for researchers who (a) have received documented training in hazardous-chemical handling under OSHA 29 CFR 1910.1450 or equivalent, (b) are working within an institutional chemical hygiene plan that names SR-17018 or a class of μ-opioid receptor agonists as authorized, (c) have the approval of their principal investigator and EHS office, and (d) where animal work is involved, are operating under an active Institutional Animal Care and Use Committee (IACUC) protocol that specifies SR-17018 or authorizes a comparable investigational compound.^[1],[2]

Undergraduate researchers should work with SR-17018 only under the direct supervision of a trained graduate student, staff scientist, or faculty member. Solo handling by trainees is not recommended.

Pregnant researchers, researchers with known opioid-use disorder, and researchers with pre-existing respiratory compromise should consult their occupational-health provider before handling SR-17018 or similar compounds.

SR-17018 is a synthetic μ-opioid receptor agonist. A compound-specific published LD₅₀, inhalation exposure limit, or reproductive-toxicity profile is not, to our knowledge, available in the peer-reviewed literature at the time of writing. In the absence of compound-specific data, it should be handled under the generic precautions applicable to synthetic opioid agonists:

• Acute toxicity (oral/dermal/inhalation). Assume category 3 or higher pending data. Small incidental exposures are unlikely to be fatal, but respiratory depression has been demonstrated at high doses in rodents.^[3]
• Serious health hazard. Repeated or chronic exposure to μ-opioid agonists can produce physical dependence and tolerance. Respiratory depression is the life-threatening risk in acute overdose.
• Environmental hazard. Treat as an aquatic toxin in the absence of compound-specific data; avoid discharge to drains.

Reference the current safety data sheet (SDS) issued with your order. SDS details may be revised between batches as additional characterization data become available.

On receipt, inspect the outer packaging for damage and the inner amber glass or polypropylene vial for integrity. A certificate of analysis (COA) accompanies every SR17 Labs shipment and should be retained for the life of the batch in your chemical inventory record. The COA records batch number, purity by HPLC, identity confirmation by NMR and mass spectrometry, and assay date.

Record the batch number against the vial, log receipt in your chemical inventory system, and verify that the received quantity matches the bill of lading. Transfer the material to your controlled-access storage location the same day it arrives; do not leave research opioids sitting on the loading dock or in a shared receiving area overnight.

If the vial appears broken, if the tamper-evident seal is missing or compromised, or if the contents appear visibly different from the COA description, do not open the package. Photograph the condition, quarantine the shipment, and contact SR17 Labs support for guidance before taking any further action.

Store sealed, dry, and protected from light. Recommended storage is standard refrigeration at 36–46°F. If solutions are prepared, aliquot and refrigerate or freeze appropriately to minimize repeated handling.

Always equilibrate a refrigerated vial to room temperature before opening. Cold vials accumulate atmospheric moisture on the cap threads on opening, which can hydrolyze sensitive compounds and complicate quantitative reweighing. Allow 20–30 minutes with the cap closed for a 1 g vial to equilibrate.

Store the compound in a secure, controlled-access location, separated from food, beverages, and unrelated chemical classes (strong oxidizers, strong acids). Maintain a chemical inventory that allows reconciliation of the current vial mass against logged withdrawals. A two-person sign-out procedure is recommended for research customers that handle multiple controlled or controlled-analog compounds.

Prepared stock solutions (see below) should be stored in labeled amber vials under refrigeration or appropriate freezer storage, with a use-by date consistent with the solvent and concentration. Re-verify potency at any ambiguous re-use.

For in-vitro assays, SR-17018 is typically dissolved in anhydrous DMSO at a working stock concentration of 10 mM (approximately 4.6 mg/mL given the compound's molar mass). This concentration is compatible with typical bench serial dilutions into aqueous assay buffer while keeping final DMSO content below 0.1% (v/v).

Weighing should occur in a fume hood on a calibrated analytical balance, with a clean anti-static weigh boat and dedicated spatula. For the 1 g vial format, consider working from a single mass transfer into an intermediate stock rather than repeatedly opening the primary vial. Filter stock solutions through a 0.22 μm PTFE syringe filter if required by the downstream assay.

For in-vivo work, dissolution protocols vary with the route of administration. The Schmid 2017 characterization used intraperitoneal and subcutaneous delivery with vehicle formulations based on DMSO, Tween-80, and saline; researchers replicating those protocols should consult the original paper directly for composition and concentration.^[3]

Aqueous solubility of SR-17018 without a co-solvent is low. Attempts to dissolve the compound directly in phosphate-buffered saline at pharmacologically meaningful concentrations will generally fail and should not be relied on for quantitative dosing.

Minimum PPE for weighing and handling solid SR-17018:

• Hand protection. Two pairs of nitrile gloves, inspected for defects before donning. Change gloves immediately if visibly contaminated. Do not reuse.
• Eye protection. ANSI-Z87-rated safety glasses with side shields, or full chemical-splash goggles when working with stock solutions.
• Body protection. Buttoned lab coat. For larger quantities (≥ 5 g open handling), consider a disposable Tyvek coverall over the lab coat.
• Respiratory protection. For routine weighing inside a certified fume hood, additional respiratory protection is not required. For bulk handling outside a fume hood — which we discourage — use a fit-tested N95 or half-face air-purifying respirator with an OV/P100 cartridge.
• Foot protection. Closed-toe shoes. No fabric uppers. Dedicated laboratory footwear is preferred.

Remove PPE before leaving the laboratory and dispose of disposable items in the laboratory's hazardous-waste stream. Wash hands thoroughly with soap and water after removing gloves, whether or not a visible exposure occurred.

All SR-17018-contaminated waste — gloves, weigh boats, pipette tips, empty vials, spent stock solutions, animal-study consumables — should be managed as hazardous chemical waste. Do not dispose of SR-17018 or its solutions in laboratory drains, standard trash, or biohazard-only waste streams.

Package solid contaminated waste in a rigid, leak-proof container labeled with the compound name, concentration or exposure category, start date, and responsible researcher. Liquid waste (DMSO stock solutions, aqueous dilutions) should be collected in a compatible sealed container, segregated from halogenated and acidic waste streams.

Contact your institution's EHS office for pickup and final disposition. Incineration at a permitted facility is the standard disposition for synthetic opioid research-compound waste in the United States; your institution's contract vendor will handle the actual incineration.

For unused bulk material that has exceeded its intended study window but is otherwise in specification, consider returning the vial to SR17 Labs rather than destroying it. We can absorb in-specification returns into the next batch release workflow under defined conditions; contact support for return authorization.

The dominant acute risk from SR-17018 exposure, by analogy to other potent μ-opioid agonists, is respiratory depression. Exposure routes to prioritize in a response plan are dermal (broken gloves), mucosal (splash to eye, mouth, nose), and inhalation (aerosolized dust during weighing outside a fume hood).

Skin contact. Remove contaminated PPE. Wash the affected area with soap and copious water for at least 15 minutes. If irritation develops or if contact was with a concentrated stock solution, seek medical evaluation.

Eye contact. Rinse at an emergency eyewash station for 15 minutes with the eyelids held open. Seek immediate medical evaluation even if symptoms resolve.

Inhalation. Move the affected person to fresh air. Loosen tight clothing. Monitor for signs of respiratory depression: slow or shallow breathing, pinpoint pupils, drowsiness, loss of consciousness. If any of these signs appear, call emergency services and administer naloxone if available and if trained to do so. Do not leave the affected person alone.

Ingestion. Do not induce vomiting. Call your local poison control center and emergency services. Provide the SR-17018 SDS and COA to responding medical personnel.

Laboratories handling SR-17018 or similar synthetic opioid research compounds should consider stocking naloxone nasal spray in the laboratory first-aid kit, and training lab members in its administration, in consultation with occupational health. This is standard practice in fentanyl-analog research settings and is increasingly recommended for any synthetic opioid research program.

Under current US transportation regulations, small quantities of SR-17018 (grams to tens of grams) ship as a non-regulated research chemical when not classified as a controlled substance at origin and destination. SR17 Labs ships under that framework domestically within the United States.

International transport is more complex. Some jurisdictions treat novel synthetic opioids as controlled by analog or by explicit class-based scheduling, and others require import permits for any μ-opioid receptor agonist regardless of scheduling. Before placing an international order, confirm that import of SR-17018 is permitted at the destination and, where required, that an import permit is in hand. SR17 Labs does not ship to destinations where the recipient has not confirmed regulatory eligibility.

Intra-institution transport — moving a vial from the loading dock to the stockroom, or between two laboratories within the same building — should follow your institution's internal chemical-transport policy. At minimum, transport should use a secondary containment tray, a direct route, and should not pass through public spaces open to unauthorized personnel.